Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial
Integrative Cancer Therapies · 2026-03 · 25
DOI: 10.1177/15347354251396002 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Integrative Cancer Therapies, online erschienen am 11.03.2026. Verfasst von Ya-Dong Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Guangzhou University of Chinese Medicine, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Colonic Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Project of State Key Laboratory of Traditional Chinese Medicine Syndrome, guangzhou municipal science and technology bureau, guangzhou university of chinese medicine.
Abstract (Originalsprache)
Background
Colorectal cancer is one of the most common and fatal cancers worldwide. Despite therapeutic advancements, patients with stage II and III colon cancer often experience recurrences and metastases, particularly to the liver, leading to suboptimal disease-free survival (DFS) rates and decreased long-term survival. Qu-Shi-Jie-Du decoction (QSJDD), a traditional Chinese herbal formula, may prevent cancer recurrence and spread by boosting immunity, reducing inflammation, and inhibiting tumour growth. Preliminary studies have demonstrated that QSJDD reduces liver metastasis in patients with colon cancer. However, robust clinical evidence is required to confirm its efficacy and safety.
Objective
This study aims to evaluate the safety and efficacy of QSJDD in preventing colon cancer recurrence and liver metastasis, thereby offering a potential adjunctive therapy to improve patient outcomes.
Methods
This multicentre, double-blind, randomised, placebo-controlled trial involves 336 high-risk stage II or III colon cancer patients from 10 Chinese hospitals. Post-surgery and chemotherapy, 168 patients will receive either QSJDD compound granules or a placebo for 6 months, with a 3-year follow-up and evaluations every 6 months. The primary endpoint is to measure the 3-year DFS rate, while secondary endpoints include 1- and 2-year DFS rates, overall survival, and changes in the Traditional Chinese Medicine Dampness Syndrome Scale. Safety and adverse events will be tracked, and blood and gut microbiomes will be analysed to assess QSJDD’s impact on delaying colon cancer metastasis.
Discussion
This trial will determine the efficacy and safety of QSJDD and provide evidence regarding its role in the adjuvant treatment of colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical College of Guangzhou University of Chinese Medicine, China.
- Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
- Guangzhou Key Laboratory of Acupuncture and Medicine Research, China.
- Shenzhen Zigzag Biotechnology Co., Ltd., China.
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China.
- State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou, China.
ORCID-Profile: Ya-Dong Chen, Zi-Yan He, Yan-Juan Zhu, Xue-Song Chang, Hai-Bo Zhang
Förderung
- The Project of State Key Laboratory of Traditional Chinese Medicine Syndrome
- guangzhou municipal science and technology bureau
- guangzhou university of chinese medicine
- The Traditional Chinese Medicine Bureau of Guangdong Province
- guangdong provincial hospital of traditional chinese medicine
- Science and Technology Planning Project of Guangdong Province
Zitieren
APA
Chen, Y. D., He, Z. Y., Zhao, W. J., He, Y. H., Liu, Y. H., Zhu, Y. J., Yu, Y. Y., Xiao, Z. Z., Chang, X. S., Liu, Z. B., & Zhang, H. B. (2026). Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial. Integrative Cancer Therapies, 25. https://doi.org/10.1177/15347354251396002
Vancouver
Chen YD, He ZY, Zhao WJ, He YH, Liu YH, Zhu YJ, et al. Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial. Integrative Cancer Therapies. 2026;25. doi:10.1177/15347354251396002
BibTeX
@article{Chen2026,
author = {Chen, Ya-Dong and He, Zi-Yan and Zhao, Wen-Jie and He, Yi-Han and Liu, Yi-Hong and Zhu, Yan-Juan and Yu, Ya-Ya and Xiao, Zhen-Zhen and Chang, Xue-Song and Liu, Zong-Bin and Zhang, Hai-Bo},
title = {Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial},
journal = {Integrative Cancer Therapies},
year = {2026},
volume = {25},
doi = {10.1177/15347354251396002}
}
EUVIMED